Novo Nordisk's CagriSema: A Breakthrough in Weight Loss for Type 2 Diabetes

Novo Nordisk's new drug, CagriSema, showed promising results in reducing weight among overweight or obese type 2 diabetes patients. During the phase III REDEFINE 2 trial, participants experienced a 15.7% reduction in body weight after 68 weeks. CagriSema combines semaglutide and cagrilintide to effectively suppress hunger.

Novo Nordisk announced on Monday the successful results of its cutting-edge drug CagriSema in combating obesity among type 2 diabetes patients. The drug achieved an average weight loss of 15.7% over 68 weeks, a significant improvement compared to the 3.1% reduction observed with a placebo.

The phase III REDEFINE 2 trial, involving approximately 1,200 participants with a BMI of 27 or more, provided valuable insights into CagriSema's potential. This study employed a flexible dosing protocol, with nearly 62% of patients reaching the highest dose by the end of the trial.

CagriSema, administered as a weekly injection, combines semaglutide and cagrilintide to suppress hunger and regulate blood glucose levels, offering a new hope for effective weight management in type 2 diabetes care.

(With inputs from agencies.)